Therapeutic Value of an Integrin Antagonist in Prostate Cancer

Author(s): Clément-Lacroix Philippe.

Journal Name: Current Drug Targets

Volume 17 , Issue 3 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

In recent decades we have seen an exponential interest in the implications of integrin receptors in cancer biology and especially in prostate tumour development. Integrins has been reported to control multiple mechanisms, such as cell survival, proliferation, differentiation, and migration. Here, we report the current understanding of the integrin signalling mechanisms in metastatic prostate tumour development, cross-talks between the primary and metastatic sites on tumour growth, interactions between tumour cells and tissue microenvironment, and epithelial-mesenchymal transition (EMT). Finally, this review presents the integrin-based chemotherapeutic agents currently under clinically consideration and provides an insight into cancer drug development using integrin as a target.

Keywords: Antagonist therapy, integrin, prostate cancer.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 17
ISSUE: 3
Year: 2016
Page: [321 - 327]
Pages: 7
DOI: 10.2174/1389450117666151209115324
Price: $58

Article Metrics

PDF: 27
HTML: 2